Autolus Therapeutics PLC Sponsored ADR

AUTL Healthcare Biotechnology

In the quarter to June 2026, revenue grew 118.4%, EPS grew 16.7% and free cash flow grew 67.6%, each against the same quarter a year earlier.

1.65 0.09 −5.17%
Market cap
$463.1M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
3/9
Altman Z
−3.17
Beneish M
n/a
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Sep '18 Dec '17
Revenue
75.39 10.12 1.70 6.36 2.33 1.72 2.91 — 1.41 —
Revenue Growth
644.94% 496.00% (73.30%) 172.96% 35.86% (41.02%) 106.68% — (16.89%) —
Gross Profit
(20.98) (1.27) 1.70 6.36 2.33 1.72 2.91 (1.71) 1.41 (1.01)
Operating Income
(270.54) (241.43) (179.70) (143.41) (165.00) (168.14) (146.06) — (57.53) (22.79)
EBT
(285.56) (219.13) (208.40) (148.57) (165.99) (166.26) (139.01) (52.03) (52.03) (22.79)
Income after Tax
(287.53) (220.66) (208.38) (148.84) (142.10) (142.09) (123.85) — (44.75) (22.79)
Net Income Common
(287.53) (220.66) (208.38) (148.84) (142.10) (142.09) (123.85) (44.75) (44.75) (44.75)
EPS (Diluted)
(1.08) (0.86) (1.20) (1.57) (1.97) (2.76) (2.88) (1.42) (1.42) (0.49)
Shares (Diluted, Weighted)
266.14 255.16 173.94 94.99 72.08 51.56 43.07 31.56 31.56 50.75
Gross Margin
(27.83%) (12.52%) 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 0.00%
EBIT Margin
(358.87%) (2,385.63%) (10,583.10%) (2,254.84%) (7,081.55%) (9,804.37%) (5,022.83%) 0.00% (4,089.05%) 0.00%
Net Profit Margin
(381.40%) (2,180.45%) (12,272.26%) (2,340.24%) (6,098.54%) (8,285.36%) (4,258.91%) 0.00% (3,180.60%) 0.00%
Free Cash Flow Margin
(412.13%) (2,382.31%) (9,221.02%) (1,936.31%) (5,438.54%) (7,722.39%) (4,131.77%) 0.00% (2,918.83%) 0.00%
EBITDA
(260.73) (233.71) (173.14) (135.99) (156.54) (162.49) (141.45) (57.23) (55.82) (21.79)
EBIT
(270.54) (241.43) (179.70) (143.41) (165.00) (168.14) (146.06) (117.88) (57.53) (22.79)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 28 Sep 2026